Natus Medical Incorporated
NTUS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.34 | -9.51 | 2.22 | -3.50 |
| FCF Yield | 7.49% | 3.84% | 4.92% | 2.70% |
| EV / EBITDA | 15.05 | 66.59 | 76.57 | 113.81 |
| Quality | ||||
| ROIC | 3.18% | -3.01% | -2.24% | -3.24% |
| Gross Margin | 57.81% | 52.09% | 58.91% | 57.27% |
| Cash Conversion Ratio | 4.86 | -2.07 | -3.83 | -1.44 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.49% | -7.83% | -0.39% | 11.61% |
| Free Cash Flow Growth | 133.86% | -52.82% | 123.53% | 56.32% |
| Safety | ||||
| Net Debt / EBITDA | -1.30 | -2.70 | -0.60 | 5.73 |
| Interest Coverage | 11.34 | -5.52 | -3.17 | -3.62 |
| Efficiency | ||||
| Inventory Turnover | 2.95 | 2.63 | 2.85 | 2.85 |
| Cash Conversion Cycle | 143.43 | 177.49 | 164.56 | 169.28 |